This analysis models the health & economic benefits of enabling substantial improvement in secondary prevention of cardiovascular disease (CVD).

Increase in the uptake of 4 high impact but underused treatments is modelled.

3 ambition scenarios are considered: Step Change Improvement, Advanced Improvement and Full Uptake.

The headline table below shows the impact of achieving Step Change – defined as a realistic near-term improvement ambition.

Bedfordshire, Luton and Milton Keynes ICB

Year 3 – Step Change Scenario

Events prevented: • 188 Heart attacks • 376 Strokes • 552 Heart failure admissions • 40 End stage kidney disease	1,156 events* ~ 8,704 bed days (excl ESKD) *Total events may not match due to rounding
Health/social care savings	£22 million
Productivity gains	£26 million
Benefit to cost ratio	4.6 (Over £4 saved for every £1 spent, with break-even for NHS in first year of Step Change)

For full report and detailed results for England and every ICB, visit:

www.into-action.health/impactreport

INTO-ACTION.HEALTH

A realistic step change improvement in secondary prevention will prevent thousands of serious cardiovascular events, deliver huge savings in health and social care, and add £ billions to the national economy in 3 years.

The CVD Prevention Challenge

Secondary prevention – using medication to treat high risk conditions like blood pressure and cholesterol – is very effective at preventing cardiovascular disease. But under use of NICE recommended, high impact treatments that prevent CVD is substantial and longstanding – with little change over many years.

The CVDACTION Health Economic Impact Model

- **4 high risk conditions**: high blood pressure, high cholesterol, chronic kidney disease and diabetes
- **4 high impact treatments** that are NICE recommended but substantially under-used (Blood pressure lowering, cholesterol lowering, renin angiotensin inhibitors, SGLT2 inhibitors)
- **4 major outcomes:** heart attack, stroke, heart failure, end stage kidney disease
- **3 scenarios:**
  1. **Step Change** as the minimum realistic near-term improvement level. For example, step change for blood pressure = 80% patients treated to target.
  2. **Advanced** (representing substantial improvement on the way to Full Uptake)
  3. **Full Uptake** (not fully achievable in practice as medicines will not be appropriate for every patient)
- **Modelled costs include** use of CVDACTION, structured support for primary care transformation and increased medication use (>90% of the total costs).

CVDACTION targets the HOW of optimising prevention in the real world, with 3 essential pillars to enable primary care teams to work differently:

1. Smart data - routinely detect patients who are not on optimal treatment, and prioritise for optimisation

2. Structured support for transformation enabling teams to adapt workforce and pathways to optimise at scale and within capacity

3. **Structured support for delivery** – supporting teams to set and achieve step-change objectives in secondary prevention

For more information on CVDACTION contact Rosa@Into-Action.Health

INTO-ACTION.HEALTH

CVDACTION Modelled Impact (Step Change Scenario)

Headline Costs and Benefits

Location	Bedfordshire, Luton and Milton Keynes Integrated Care Board
CVDACTION optimisation cohort	All
Number of patients optimised in year 1	45,096

	After 3 years	After 5 years
Events Prevented		
Myocardial infarctions	188	307
Strokes (ischaemic)	376	609
Heart failure admissions	552	887
End stage kidney disease	40	64
Total	**1,156**	**1,867**
Costs to the Health Care System	**£10m**	**£16m**
Benefits		
Health system efficiencies	£17m	£32m
Social care efficiencies	£5m	£11m
Productivity gained	£26m	£54m
Total	**£48m**	**£97m**
Total Benefits to Costs Ratio (Gross)	**4.6**	**6.0**



All costs and benefits are discounted

INTO-ACTION.HEALTH

CVDACTION: Costs and Benefits by Year

Location: Bedfordshire, Luton and Milton Keynes Integrated Care Board

Scenario: Step Change

RESULTS (CUMULATIVE)

	After 1 year	After 2 years	After 3 years	After 4 years	After 5 years	After 10 years	After 15 years
Number avoided with CVDACTION							
Myocardial Infarctions	63	126	188	248	307	588	835
Strokes	128	254	376	493	609	1,140	1,606
Heart failure admissions	190	375	552	722	887	1,642	2,274
End stage kidney disease	14	27	40	52	64	120	167
Costs of CVDACTION and treatment (discounted)							
CVDACTION	£229,576	£229,576	£229,576	£229,576	£229,576	£229,576	£229,576
Transformation cost	£286,970	£286,970	£286,970	£286,970	£286,970	£286,970	£286,970
Treatment	£3,548,808	£6,801,975	£9,896,079	£12,840,265	£15,642,749	£27,788,383	£37,387,602
Total	**£4,065,354**	**£7,318,521**	**£10,412,625**	**£13,356,811**	**£16,159,295**	**£28,304,928**	**£37,904,147**
Value by economic category (discounted)							
Health costs avoided	£4,727,869	£10,495,637	£17,092,862	£24,277,522	£31,960,463	£74,007,762	£115,722,156
Social care costs avoided	£1,019,914	£2,777,794	£5,164,663	£8,071,359	£11,422,526	£32,340,694	£55,839,231
Informal care costs avoided	£5,488,586	£12,861,339	£21,842,300	£32,080,987	£43,449,625	£110,065,892	£181,548,925
Lost productivity avoided	£509,868	£1,969,530	£4,218,313	£7,101,935	£10,497,193	£32,105,415	£56,158,119
Total	**£11,746,237**	**£28,104,300**	**£48,318,137**	**£71,531,803**	**£97,329,806**	**£248,519,762**	**£409,268,430**
Value by clinical event (discounted)							
Myocardial Infarctions	£949,138	£2,148,872	£3,541,592	£5,096,791	£6,764,775	£16,194,354	£25,725,865
Strokes	£9,623,933	£22,242,766	£37,418,569	£54,571,865	£73,519,708	£183,526,881	£300,732,865
Heart failure admissions	£588,396	£1,932,421	£3,875,668	£6,283,650	£9,062,664	£25,948,197	£43,906,769
End stage kidney disease	£584,772	£1,780,241	£3,482,309	£5,579,497	£7,982,660	£22,850,330	£38,902,931
Total	**£11,746,237**	**£28,104,300**	**£48,318,137**	**£71,531,803**	**£97,329,806**	**£248,519,762**	**£409,268,430**
Benefit to cost ratio (Gross)							
Health costs avoided	1.2	1.4	1.6	1.8	2.0	2.6	3.1
Social care costs avoided	0.3	0.4	0.5	0.6	0.7	1.1	1.5
Informal care costs avoided	1.4	1.8	2.1	2.4	2.7	3.9	4.8
Lost productivity avoided	0.1	0.3	0.4	0.5	0.6	1.1	1.5
Total	**2.9**	**3.8**	**4.6**	**5.4**	**6.0**	**8.8**	**10.8**

*Numbers less than 10 suppressed

INTO-ACTION.HEALTH

CVDACTION Optimisation Cohorts Analysis After 3 Years

Location

Bedfordshire, Luton and Milton Keynes Integrated Care Board

Step Change Scenario After 3 Years

Optimisation Cohort	Heath System Costs	CVD Events Prevented[1]	Health System Efficiencies	*Social Care Efficencies*	*Informal Care Avoided*	*Productivity Gained*	*Total Benefits*
Hypertension							
1 .Blood pressure not treated to target	£665,952	533	£8,051,852	*£3,084,101*	*£13,069,158*	*£1,815,447*	*£26,020,557*
Cholesterol							
2. CVD not on Lipid Lowering Therapy (LLT)	£105,237	38	£733,432	*£311,580*	*£1,320,332*	*£140,858*	*£2,506,202*
3. CVD on suboptimal dose or intensity of statin	£188,530	42	£667,701	*£200,246*	*£845,657*	*£142,793*	*£1,856,396*
4. CVD on max statin but not treated to target	£402,618	17	£333,135	*£106,820*	*£455,785*	*£63,251*	*£958,991*
Chronic Kidney Disease							
5. RAA indicated but not prescribed	£14,302	16	£317,945	*£54,026*	*£232,380*	*£91,574*	*£695,925*
6. SGLT2i indicated but not prescribed	£1,722,094	74	£625,517	*£0*	*£0*	*£226,335*	*£851,853*
7. CVD and Statin not prescribed	£15,441	10	£207,470	*£89,616*	*£383,370*	*£37,138*	*£717,594*
8. BP not treated to target	£22,819	34	£534,207	*£207,600*	*£875,896*	*£121,115*	*£1,738,818*
Diabetes							
9. RAA indicated but not prescribed	£199,714	146	£2,700,828	*£495,669*	*£2,085,364*	*£781,501*	*£6,063,363*
10. SGLT2i indicated but not prescribed	£6,966,938	148	£1,307,227	*£0*	*£0*	*£442,792*	*£1,750,019*
11. DM and HTN with BP not treated to target	£92,698	90	£1,461,552	*£552,767*	*£2,313,333*	*£326,439*	*£4,654,091*
12. DM with CVD not on LLT	£16,283	8	£151,996	*£62,237*	*£261,024*	*£29,069*	*£504,327*
Total	**£10,412,625**	**1,156**	**£17,092,862**	*£5,164,663*	*£21,842,300*	*£4,218,313*	*£48,318,137*

All costs and benefits are discounted

1 *Events include heart attacks, strokes, heart failure admissions and end stage kidney disease.*